Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Low/Intermediate Risk MDS Receiving Hypomethylating Agents
NCT00321711Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2006
- Primary completion
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of romiplostim in Thrombocytopenia (5 arms), sponsored by Amgen. Primary endpoint: Occurrence of a Clinically Significant Thrombocytopenic Event. Started Oct 2006; status: completed.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00321711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321711.